{
    "Trade/Device Name(s)": [
        "LIAISON MeMed BV",
        "LIAISON MeMed BV Control Set"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K213936",
    "Predicate Device Reference 510(k) Number(s)": [
        "K210254"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QPS",
        "QCH"
    ],
    "Summary Letter Date": "December 15, 2021",
    "Summary Letter Received Date": "December 16, 2021",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3215"
    ],
    "Regulation Name(s)": [
        "Device To Detect And Measure Non-Microbial Analyte(s) In Human Clinical Specimens To Aid In Assessment Of Patients With Suspected Sepsis"
    ],
    "Analyte Class(es)": [
        "immunology",
        "chemistry"
    ],
    "Analyte(s)": [
        "TRAIL",
        "IP-10",
        "CRP"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Semi-quantitative immunoassay",
        "Protein measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control Set",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON MeMed BV chemiluminescent immunoassay measuring TRAIL, IP-10, and CRP for differentiating bacterial from viral infection",
    "Indications for Use Summary": "Aid to differentiate bacterial from viral infection in adult and pediatric patients with suspected acute bacterial or viral infection, presenting to emergency department or urgent care, with samples collected at hospital admission and symptoms for seven days or less, used in conjunction with clinical assessment and other laboratory findings",
    "fda_folder": "Microbiology"
}